Clinical Trials
163 trialsCarboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
FASCINATE-N
Fudan University
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
NeoTOP
Sun Yat-sen University
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
RenJi Hospital
TARMAC
University College Hospital, Ibadan
I-SPY
QuantumLeap Healthcare Collaborative
NeoTHERa
University of Kansas Medical Center
EmpowHER 208
Jazz Pharmaceuticals
NeoTRACT
University of Kansas Medical Center
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
TELESCOPE
MedSIR
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
DespaTIL
D'Or Institute for Research and Education
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
PRISM-TNBC
Shandong Cancer Hospital and Institute
MK-5890-003
Merck Sharp & Dohme LLC
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
University of California, San Francisco
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Triple-B
The Netherlands Cancer Institute
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
NeoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Hebei Medical University Fourth Hospital
ARIADNE
Karolinska University Hospital
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
Henan Cancer Hospital
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting
Oslo University Hospital
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
PHERGain
MedSIR
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
CADENCE
Baylor Breast Care Center
ADAPT
West German Study Group
RESPONSE
Baylor Breast Care Center
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
CA225200
US Oncology Research
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
SAFIR02_Breast
UNICANCER
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
NeoTOP
UNICANCER